腺苷A2A受体激动剂减轻烧伤继发性进展
研究采用猪梳状烧伤模型,评估腺苷A2A受体(A2AR)激动剂ATL-1223对烧伤继发性进展的影响,主要观察坏死间隙发生率。结果显示ATL-1223降低伤后4天内坏死间隙发展速率,减少真皮中性粒细胞浸润和微血管血栓形成,并减轻烧伤深度。
要点
- ATL-1223降低伤后4天坏死间隙发展速率(p<.05)。
- ATL-1223减少48小时真皮中性粒细胞浸润(p=.029)。
- ATL-1223减少微血管血栓及减轻烧伤深度(p=.038)。
核心结论
- A2AR激动剂可通过抑制局部炎症反应减轻烧伤继发性进展。
研究设计与样本
- 采用猪梳状烧伤模型,每头猪8个全层烧伤(每个梳状烧伤含4个梳齿和3个间隙),温度115°C、3 kg压力、30秒。
- 动物随机分组(每组4头),接受ATL-1223(3 ng/kg/min,静脉输注6小时)或载体对照。
- 主要结局为坏死间隙形成,并进行组织学评估。
主要发现
- 分析未烧伤间隙(每组72个)显示,ATL-1223降低伤后前4天坏死间隙发展速率(p<.05)。
- ATL-1223显著降低烧伤后48小时真皮中性粒细胞浸润(14.63±4.30 vs 29.71±10.76 个/高倍视野,p=.029)。
- ATL-1223组伤后第4天微血管血栓形成的间隙比例更低(18.8% vs 56.3%,p=.002)。
- 伤后2周,ATL-1223组烧伤部位(邻近间隙)损伤深度显著降低(2.91±0.47 vs 3.28±0.58 mm,p=.038)。
临床怎么用
- A2AR激动剂可能作为辅助治疗减轻烧伤继发性进展,需进一步临床验证。
- 延长给药策略可能带来额外获益并改善美容 outcome。
局限性
- 研究为动物模型(猪),结果外推到人需谨慎。
- 样本量较小(每组4头猪)。
- 给药方案为单次6小时输注,未评估延长给药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current burn therapy is largely supportive with limited therapies to curb secondary burn progression. Adenosine 2A receptor (A2AR) agonists have anti-inflammatory effects with decreased inflammatory cell infiltrate and release of proinflammatory mediators. Using a porcine comb burn model, we examined whether A2AR agonists could mitigate burn progression. Eight full-thickness comb burns (four prongs with three spaces per comb) per pig were generated with the following specifications: temperature 115°C, 3-kg force, and 30-second application time. In a randomized fashion, animals (four per group) were then treated with A2AR agonist (ATL-1223, 3 ng/kg/min, intravenous infusion over 6 hours) or vehicle control. Necrotic interspace development was the primary outcome and additional histologic assessments were conducted. Analysis of unburned interspaces (72 per group) revealed that ATL-1223 treatment decreased the rate of necrotic interspace development over the first 4 days following injury (p < .05). Treatment significantly decreased dermal neutrophil infiltration at 48 hours following burn (14.63 ± 4.30 vs 29.71 ± 10.76 neutrophils/high-power field, p = .029). Additionally, ATL-1223 treatment was associated with fewer interspaces with evidence of microvascular thrombi through postburn day 4 (18.8% vs 56.3%, p = .002). Two weeks following insult, the depth of injury at distinct burn sites (adjacent to interspaces) was significantly reduced by ATL-1223 treatment (2.91 ± 0.47 vs 3.28 ± 0.58 mm, p = .038). This work demonstrates the ability of an A2AR agonist to mitigate burn progression through dampening local inflammatory processes. Extended dosing strategies may yield additional benefit and improve cosmetic outcome in those with severe injury.
引用
- Haywood N, Byler MR, Zhang A, et al. Secondary Burn Progression Mitigated by an Adenosine 2A Receptor Agonist. J Burn Care Res. 2022. PMID: 33769530. doi:10.1093/jbcr/irab053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。